Evidence map›Paper›PMID 38457653›Full record

ArticleBiomacromolecules2024

Postpolymerization Modification of Poly(2-vinyl-4,4-dimethyl azlactone) as a Versatile Strategy for Drug Conjugation and Stimuli-Responsive Release.

Sk Arif Mohammad, Veeresh B Toragall, Alex Fortenberry, Oluwaseyi Shofolawe-Bakare, Suresh Sulochana, Katie Heath, Iyanuoluwani Owolabi, Garrett Tassin, Alex S Flynt, Adam E Smith and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomacromolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Sk Arif MohammadDepartment of Biomedical Engineering, University of Mississippi, University, Mississippi 38677, United States.
Veeresh B ToragallDepartment of Biomedical Engineering, University of Mississippi, University, Mississippi 38677, United States.
Alex FortenberryDepartment of Chemical Engineering, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0003-1629-6152
Oluwaseyi Shofolawe-BakareDepartment of Chemical Engineering, University of Mississippi, University, Mississippi 38677, United States.
Suresh SulochanaCenter of Biomedical Research Excellence in Natural Products Neuroscience, University of Mississippi, University, Mississippi 38677, United States.
Katie HeathCenter of Biomedical Research Excellence in Natural Products Neuroscience, University of Mississippi, University, Mississippi 38677, United States.
Iyanuoluwani OwolabiCenter for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, Mississippi 39406, United States.
Garrett TassinCenter for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, Mississippi 39406, United States.
Alex S FlyntCenter for Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, Mississippi 39406, United States.
Adam E SmithDepartment of Biomedical Engineering, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0003-1733-443X
Thomas WerfelDepartment of Biomedical Engineering, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0002-6005-1243
University of Mississippi · USUniversity of Southern Mississippi · USUniversity of Mississippi Medical Center · US

Funding

Tracking Glycosylation State with Fluorinated Glycosides ProbesP20GM130460 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI Joshua S Sharp · 2020 to 2026
$17.9M
Validation of the Regulatory Potential of Tailed MirtronsR15GM120716 · NIGMS · UNIVERSITY OF SOUTHERN MISSISSIPPI · PI FLYNT, ALEX · 2016 to 2016
$437k
Laser spectroscopic instrumentation for isotopic sensing of biogenic Nitric OxideR21GM103460 · NIGMS · PRINCETON UNIVERSITY · PI WYSOCKI, GERARD · 2012 to 2012
$190k
NIGMS NIH HHS P20 GM130460NIGMS NIH HHS R15 GM120716NIGMS NIH HHS R21 GM103460
6 · The paper itself

Abstract

Postpolymerization modification of highly defined "scaffold" polymers is a promising approach for overcoming the existing limitations of controlled radical polymerization such as batch-to-batch inconsistencies, accessibility to different monomers, and compatibility with harsh synthesis conditions. Using multiple physicochemical characterization techniques, we demonstrate that poly(2-vinyl-4,4-dimethyl azlactone) (PVDMA) scaffolds can be efficiently modified with a coumarin derivative, doxorubicin, and camptothecin small molecule drugs. Subsequently, we show that coumarin-modified PVDMA has a high cellular biocompatibility and that coumarin derivatives are liberated from the polymer in the intracellular environment for cytosolic accumulation. In addition, we report the pharmacokinetics, biodistribution, and antitumor efficacy of a PVDMA-based polymer for the first time, demonstrating unique accumulation patterns based on the administration route (i.e., intravenous vs oral), efficient tumor uptake, and tumor growth inhibition in 4T1 orthotopic triple negative breast cancer (TNBC) xenografts. This work establishes the utility of PVDMA as a versatile chemical platform for producing polymer-drug conjugates with a tunable, stimuli-responsive delivery.

Indexed as

LactonesNeoplasmsPolymersDoxorubicinHumansPolyvinyl ChloridePolyvinylsTissue DistributionDoxorubicinLactonespoly(2-vinyl-4,4-dimethyl azlactone)PolymersPolyvinyl ChloridePolyvinyls

Identifiers

PMID38457653
PMCPMC11194783
OpenAlexW4392579905

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.